secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001367644-23-000091
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions closes sale of travel health business to Bavarian Nordic for $270M upfront
--------------------------------------------------------------------------------

- Emergent closed sale of travel health business to Bavarian Nordic on May 15, 2023 for $270M upfront cash.
- Potential milestone payments: up to $80M for CHIKV VLP development/approval and $30M earnout on 2026 net sales.
- Assets sold include typhoid vaccine Vivotif, cholera vaccine Vaxchora, CHIKV VLP candidate, Bern manufacturing site, San Diego development facilities.
- Majority of employees supporting these products and facilities are joining Bavarian Nordic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/0001367644-23-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000091/ebs-20230515.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer